Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fluconazole · 1 trial · 1 indication
Concentration maximum
Area under the plasma concentration time curve from time 0 to the last data point above the lower limit of quantification
| Arm | Type | Description |
|---|---|---|
| Fluconazole, period 1 | EXPERIMENTAL | Subjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 1 after an overnight fast of at least 10 hours |
| Fluconazole, period 2 | EXPERIMENTAL | Subjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 2 after an overnight fast of at least 10 hours |
| Name | Type | Description |
|---|---|---|
| Fluconazole (BAYT006267) 150 mg capsules | DRUG | Fluconazole 150 mg |
| Fluconazole 150 mg capsules (DiflucanTM) | DRUG | Fluconazole 150 mg |
Inclusion Criteria: * Healthy males in the age between 18 and 50 years * Subjects with a body weight of at least 50 kg and a BMI between 18.5 and 30.0 kg/m2 * Subjects had to be willing to use an acceptable method of contraception (double barrier) during the study and 2 weeks after the end of the s...
Fluconazole is a small molecule drug developed by Bayer AG under the code BAYT006267, formulated as 150 mg capsules. It has been studied in a Phase 1 bioequivalence trial in Germany. The trial enrolled 26 healthy male volunteers and was completed. Fluconazole is also known by its developmental code BAYT006267.
Fluconazole is developed by Bayer AG, which trades on the OTC market under the ticker BAYRY. The drug is also identified by the developmental code BAYT006267. Bayer AG conducted a Phase 1 bioequivalence trial of two different fluconazole formulations to demonstrate equal blood concentrations.
Fluconazole is in Phase 1 clinical development. A single Phase 1 bioequivalence trial has been completed, and no active trials are ongoing. The trial was conducted in Germany and enrolled 26 healthy male volunteers. Fluconazole is investigational and has not been approved by the FDA for any indication.
Fluconazole has been studied in one completed Phase 1 clinical trial, NCT03929861, titled "Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations." The trial was conducted in Germany, enrolled 26 healthy male volunteers, and used a randomized, controlled design. No active trials are currently listed.
Yes, Fluconazole is also known as BAYT006267. The 150 mg capsules are identified by the developmental code BAYT006267. This alternative name may appear in regulatory filings, clinical trial registries, or scientific literature. Both names refer to the same small molecule drug developed by Bayer AG.